Aptorum Group Limited (NASDAQ:APM) Short Interest Down 81.4% in May

Aptorum Group Limited (NASDAQ:APM) was the target of a large drop in short interest during the month of May. As of May 29th, there was short interest totaling 2,482 shares, a drop of 81.4% from the May 14th total of 13,376 shares. Based on an average daily volume of 65,802 shares, the short-interest ratio is currently 0.0 days. Currently, 0.1% of the shares of the company are short sold.

Aptorum Group Trading Down 4.3%

Shares of NASDAQ:APM opened at $1.12 on Wednesday. Aptorum Group has a 52-week low of $0.65 and a 52-week high of $4.47. The company has a 50-day simple moving average of $0.90 and a 200 day simple moving average of $0.98.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of Aptorum Group from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 4th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Aptorum Group Company Profile

Aptorum Group Ltd. (NASDAQ: APM) is a global biopharmaceutical company incorporated under the laws of the Cayman Islands and headquartered in Hong Kong. Since its Nasdaq listing in 2018, the company has focused on the discovery, development and commercialization of novel therapeutics and diagnostic products. Aptorum’s research efforts are aimed at addressing unmet medical needs across oncology, metabolic disorders, infectious diseases and neurological conditions.

The company’s diversified pipeline includes both small-molecule and biologic drug candidates, as well as companion diagnostic tools.